Clinical trials: Small Pox
HIV Infections
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)
To evaluate, in healthy HIV-1 seronegative vaccinia-immune and vaccinia-naive volunteers, the safety and immunogenicity of an HIV-1 candidate vaccine (TBC-3B) consisting of a live recombinant vaccinia virus expressing the env…
- Trial name
- NCT00000767
- Testing
- TBC-3B Vaccine, Smallpox Vaccine
- Where
- 5 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
To define the safety of vaccination with APSV as determined by the reactogenicity of the vaccine and the development of expected and un-expected adverse events associated with vaccination.
- Trial name
- NCT00038987
- Testing
- Wetvax (APSV)
- Where
- 4 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox, Anthrax
VHA Clinicians and Bioterror Events: Interactive Web-based Learning
Our 4-year project uses public domain software and content developed by a University of Alabama at Birmingham (UAB) team and updates, refines, and tailors it to the unique clinician populations and electronic educational…
- Trial name
- NCT00123396
- Testing
- BioCASES and BioTESTS
- Where
- 9 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Smallpox
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
The purpose of this study is to gather information on the safety and the effectiveness of an investigational vaccine for the prevention of smallpox disease.
- Trial name
- NCT00079820
- Testing
- ACAM3000 MVA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations
- Trial name
- NCT00316589
- Testing
- IMVAMUNE (MVA-BN)
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Smallpox, Mpox
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.
- Trial name
- NCT05995275
- Testing
- mRNA-1769
- Where
- 12 sites in United Kingdom
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Smallpox
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
The currently available stock of smallpox vaccine would be insufficient in the face of an incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine are urgently needed because previous manufacturing…
- Trial name
- NCT01317238
- Testing
- smallpox vaccine CJ-50300
- Where
- South Korea
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Orthopoxviral Disease
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers.
- Trial name
- 246-Safety (NCT00907803)
- Testing
- ST-246 400 mg, ST-246 600 mg
- Where
- 3 sites in United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies
Smallpox
MVA Post-Event: Administration Timing and Boost Study
The purpose of this study is to evaluate an investigational smallpox vaccine, called IMVAMUNE®, with respect to safety and immune (body's defense system) response.
- Trial name
- NCT00437021
- Testing
- Live vaccinia virus vaccine, MVA Smallpox Vaccine
- Where
- 7 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
This study is designed to evaluate the immunogenicity profile of JYNNEOS® when 2 doses are administered subcutaneously (SC) 4 weeks apart; and potential immunological interference while concomitantly administering TPOXX or…
- Trial name
- NCT04957485
- Testing
- Tecovirimat, Smallpox and Mpox Vaccine
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies
HIV Infections, HIV Seronegativity
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
AMENDED 8/94: To expand the safety and immunogenicity profile of MN rgp160 vaccine (Immuno-AG) by administering a higher dose (800 mcg) at 0, 1, 6, and 12 months and 0, 2, 8 and 14 months (these two schedules were compared in VEU…
- Trial name
- NCT00001043
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Smallpox
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
The purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with HIV infection
- Trial name
- NCT00282581
- Testing
- MVA Smallpox Vaccine
- Where
- 6 sites in United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Smallpox
Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects
The purpose of this study is to collect information on the safety, tolerability and immunogenicity of an investigational smallpox vaccine at different doses and using different routes of administration in vaccinia-naive and…
- Trial name
- NCT00189943
- Testing
- MVA-BN
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Smallpox
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered twice daily (BID) for 28 days in adult subjects.
- Trial name
- NCT04971109
- Testing
- TPOXX
- Where
- 9 sites in United States
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies
Smallpox
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
This is a Phase I/II study evaluating the safety and immunogenicity of LC16m8, a modified vaccinia vaccine. After consent and thorough screening (including safety labs, EKG, and medical history), healthy, previously unvaccinated…
- Trial name
- NCT00103584
- Testing
- LC16m8 Smallpox Vaccine
- Where
- 4 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- VaxGen
Smallpox
Dressing Preparations for Smallpox
The primary purpose of this study is to find out the risk of spreading the vaccine virus, vaccinia, from the smallpox vaccination site when different types of bandages are used to cover the site.
- Trial name
- NCT00063856
- Testing
- Wetvax (APSV)
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox
Human Immune Responses Smallpox
The purpose of this study is to attempt to identify the immune response of healthy adults to an investigational dilution of the Dryvax smallpox vaccine.
- Trial name
- NCT00068198
- Testing
- Dryvax
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.
- Trial name
- NCT00053495
- Testing
- Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax
- Where
- 4 sites in United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Smallpox
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
Safety and PK study in adults weighing more than 120 kg
- Trial name
- NCT04392739
- Testing
- Tpoxx
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies
Smallpox
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment.
- Trial name
- NCT00050505
- Testing
- Live vaccinia virus vaccine
- Where
- 7 sites in United States
- Volunteers
- 927 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)